These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 20032006

  • 21. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J, Mira JA, López-Cortés LF, Santos I, Girón-González JA, González-Serrano M, Merino D, Hernández-Quero J, Rivero A, Merchante N, Trastoy M, Carrillo-Gómez R, Arizcorreta-Yarza A, Gómez-Mateos J, Pineda JA.
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [Abstract] [Full Text] [Related]

  • 22. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients.
    Duclos-Vallée JC, Vittecoq D, Teicher E, Feray C, Roque-Afonso AM, Lombès A, Jardel C, Gigou M, Dussaix E, Sebagh M, Guettier C, Azoulay D, Adam R, Ichaï P, Saliba F, Roche B, Castaing D, Bismuth H, Samuel D.
    J Hepatol; 2005 Mar; 42(3):341-9. PubMed ID: 15710216
    [Abstract] [Full Text] [Related]

  • 23. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, Da Silva B.
    Clin Infect Dis; 2005 Oct 15; 41(8):1186-95. PubMed ID: 16163639
    [Abstract] [Full Text] [Related]

  • 24. A switch to Raltegravir improves antiretroviral associated hepatotoxicity in individuals co-infected with HIV and hepatitis C.
    Cevik M, Katsarolis I, Singh GJ, Nelson M.
    J Infect; 2014 Aug 15; 69(2):190-3. PubMed ID: 24793307
    [Abstract] [Full Text] [Related]

  • 25. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection.
    Moore E, Beadsworth MB, Chaponda M, Mhango B, Faragher B, Njala J, Hofland HW, Davies J, Hart IJ, Beeching NJ, Zijlstra EE, van Oosterhout JJ.
    J Infect; 2010 Jul 15; 61(2):155-63. PubMed ID: 20470823
    [Abstract] [Full Text] [Related]

  • 26. High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
    Bani-Sadr F, Goderel I, Morand P, Payan C, Lunel F, Pol S, Perronne C, Carrat F, Cacoub P.
    AIDS; 2007 Jul 31; 21(12):1645-8. PubMed ID: 17630563
    [Abstract] [Full Text] [Related]

  • 27. Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors.
    Jain MK, Aragaki C, Fischbach L, Gibson S, Arora R, May L, Vardhineni K, Lee WM.
    HIV Med; 2007 Nov 31; 8(8):491-7. PubMed ID: 17944681
    [Abstract] [Full Text] [Related]

  • 28. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors.
    Bani-Sadr F, Carrat F, Bedossa P, Piroth L, Cacoub P, Perronne C, Degott C, Pol S, ANRS HC02 - Ribavic Study team.
    AIDS; 2006 Feb 28; 20(4):525-31. PubMed ID: 16470116
    [Abstract] [Full Text] [Related]

  • 29. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
    Pineda JA, Santos J, Rivero A, Abdel-Kader L, Palacios R, Camacho A, Lozano F, Macías J, Liverey Study Investigator Team.
    J Antimicrob Chemother; 2008 Apr 28; 61(4):925-32. PubMed ID: 18276600
    [Abstract] [Full Text] [Related]

  • 30. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
    Bongiovanni M, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Biagio A, Chiesa E, Tordato F, Bini T, Monforte Ad.
    Int J Antimicrob Agents; 2005 Jul 28; 26(1):88-91. PubMed ID: 15878262
    [Abstract] [Full Text] [Related]

  • 31. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
    Phillips E, Gutiérrez S, Jahnke N, Yip B, Lima VD, Hogg RS, Harrigan PR, Montaner JS.
    AIDS; 2007 Jul 31; 21(12):1561-8. PubMed ID: 17630551
    [Abstract] [Full Text] [Related]

  • 32. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT.
    AIDS; 2006 May 12; 20(8):1171-9. PubMed ID: 16691069
    [Abstract] [Full Text] [Related]

  • 33. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
    Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R, Palella F.
    Clin Infect Dis; 2008 Jul 15; 47(2):250-7. PubMed ID: 18532884
    [Abstract] [Full Text] [Related]

  • 34. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD, HepaI.Co.N.A. Study Group, Italian Cohort Naive for Antiretrovirals Study Group.
    Clin Infect Dis; 2005 Jun 15; 40(12):e101-9. PubMed ID: 15909251
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals.
    Taramasso L, Madeddu G, Ricci E, De Socio GV, Menzaghi B, Orofino G, Passerini S, Franzetti M, Maggi P, Dentone C, Martinelli C, Celesia BM, Penco G, Libertone R, Quirino T, Bonfanti P, Di Biagio A, CISAI Study Group.
    Biomed Pharmacother; 2015 Feb 15; 69():233-6. PubMed ID: 25661363
    [Abstract] [Full Text] [Related]

  • 39. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.
    Mangiafico L, Perja M, Fusco F, Riva S, Mago D, Gringeri A.
    Haemophilia; 2012 Jan 15; 18(1):108-11. PubMed ID: 21762404
    [Abstract] [Full Text] [Related]

  • 40. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.
    Blanco F, Barreiro P, Ryan P, Vispo E, Martín-Carbonero L, Tuma P, Labarga P, Medrano J, González-Lahoz J, Soriano V.
    J Viral Hepat; 2011 Jan 15; 18(1):11-6. PubMed ID: 20088890
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.